Modelling the Potential Health Impact of the COVID-19 Pandemic on a Hypothetical European Country

A SEIR simulation model for the COVID-19 pandemic was developed (http://covidsim.eu) and applied to a hypothetical European country of 10 million population. Our results show which interventions potentially push the epidemic peak into the subsequent year (when vaccinations may be available) or which fail. Different levels of control (via contact reduction) resulted in 22% to 63% of the population sick, 0.2% to 0.6% hospitalised, and 0.07% to 0.28% dead (n=6,450 to 28,228).

[1]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[2]  E. Susser,et al.  The Psychological Impact of the SARS Epidemic on Hospital Employees in China: Exposure, Risk Perception, and Altruistic Acceptance of Risk , 2009, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[3]  Kai Kupferschmidt,et al.  China’s aggressive measures have slowed the coronavirus. They may not work in other countries , 2020 .

[4]  Jon Cohen,et al.  Mass testing, school closings, lockdowns: Countries pick tactics in ‘war’ against coronavirus , 2020 .

[5]  Ruiyun Li,et al.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) , 2020, Science.

[6]  Wenzhong Liu,et al.  COVID-19: CRISPR/Cas-like System of nsp3 Promotes the Mutant Recombination and Drug Resistance , 2021 .

[7]  R. Eggo,et al.  Feasibility of controlling 2019-nCoV outbreaks by isolation of cases and contacts , 2020, medRxiv.

[8]  C. Whittaker,et al.  Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand , 2020 .

[9]  P. Klepac,et al.  Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts , 2020, The Lancet Global Health.

[10]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[11]  A. Tatem,et al.  Effect of non-pharmaceutical interventions for containing the COVID-19 outbreak in China , 2020, medRxiv.

[12]  G. Chowell,et al.  Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  China Cdc Weekly.  The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 , 2020, China CDC weekly.

[14]  D. Cummings,et al.  Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions , 2020, medRxiv.

[15]  中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组.  The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China./ 新型冠状病毒肺炎流行病学特征分析 , 2020 .

[16]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[17]  Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China , 2020, Nature Medicine.

[18]  Ruiyun Li,et al.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (COVID-19) , 2020, medRxiv.

[19]  N. Wilson,et al.  Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality , 2020, Emerging infectious diseases.

[20]  A. Flahault,et al.  Mortality burden of the 1918–1919 influenza pandemic in Europe , 2009, Influenza and other respiratory viruses.

[21]  Tobias Bleicker,et al.  Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster , 2020, medRxiv.

[22]  Marie E Killerby,et al.  Human coronavirus circulation in the United States 2014–2017☆ , 2018, Journal of Clinical Virology.

[23]  G. Chowell,et al.  Estimating the risk of 2019 Novel Coronavirus death during the course of the outbreak in China, 2020 , 2020, medRxiv.

[24]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[25]  S. Eubank,et al.  Commentary on Ferguson, et al., “Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand” , 2020, Bulletin of Mathematical Biology.

[26]  S. Ramalingam,et al.  Association between viral seasonality and meteorological factors , 2019, Scientific Reports.

[27]  Jon Cohen.  Why do dozens of diseases wax and wane with the seasons—and will COVID-19? , 2020 .

[28]  J. Rocklöv,et al.  The reproductive number of COVID-19 is higher compared to SARS coronavirus , 2020, Journal of travel medicine.

[29]  M. K. Moran,et al.  Understanding, compliance and psychological impact of the SARS quarantine experience , 2007, Epidemiology and Infection.

[30]  An Pan,et al.  Evolving Epidemiology and Impact of Non-pharmaceutical Interventions on the Outbreak of Coronavirus Disease 2019 in Wuhan, China , 2020, medRxiv.